Buy me a coffee
Home › FDA recalls › Semaglutide-Glycine-Cyanocobalamin Injectable
CLASS II · ModerateFDA

PAYLESS COMPOUNDERS, LLC recalls Semaglutide-Glycine-Cyanocobalamin Injectable

📅 Mar 6, 2026 · 📍 OR
Recalling company
PAYLESS COMPOUNDERS, LLC
Product
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Reason
Lack of Assurance of Sterility
Classification
Class II – may cause temporary or medically reversible health consequences
Recall date
Mar 6, 2026
Reported
Apr 22, 2026
Distribution
OR
Status
Ongoing
Quantity
91 vials
Lot / codes
Lot Number [email protected]
Company location
Beaverton, OR
Recall type
Voluntary: Firm initiated
Recall number
D-0471-2026
Agency
U.S. Food and Drug Administration (FDA)

View official FDA notice ↗ Search recall number D-0471-2026 in the FDA Enforcement Report. Also see FDA recall press releases.

If you use this product, check the lot, NDC or model number against the official notice and follow its instructions. Do not stop a prescribed medicine or remove a medical device without talking to your doctor or pharmacist. Report problems to FDA MedWatch. FoodRecallNow summarizes public FDA data and is not medical advice.